Pascal Duijf

APrf Pascal Duijf

Enterprise Fellow

Centre for Cancer Biology

College of Health

Eligible to supervise Masters and PhD - email supervisor to discuss availability.


Associate Professor Pascal Duijf received a PhD degree in Human Genetics from Radboud University Nijmegen in the Netherlands. As a postdoctoral fellow, he trained in cancer biology and genetics at Memorial Sloan-Kettering Cancer Center in New York. He then moved to Brisbane, first to University of Queensland and then to Queensland University of Technology, to establish and lead a research group studying genomic instability in cancer. Currently, he is an Enterprise Fellow at UniSA, within the Centre for Cancer Biology and UniSA Clinical and Health Sciences. His research aims to study genomic instability in cancer in order to understand underlying mechanisms and develop new treatment options for patients. To that end, his group uses a broad range of wet-lab and dry-lab tools, including in cell biology, genome engineering, mouse models, pathology, cancer genomics, bioinformatics and computational biology.

Year Citation
2025 Jakobsen, M. K., Traynor, S., Nielsen, A. Y., Dahl, C., Staehr, M., Jakobsen, S. T., . . . Gjerstorff, M. F. (2025). Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibition. Journal Of Experimental & Clinical Cancer Research, 44(1, article no. 21), 1-15.
DOI
2025 Perera, G. S., Huang, X., Bagherjeri, F. A., Joglekar, C. M., Leo, P., Duijf, P., . . . Punyadeera, C. (2025). Rapid and selective detection of TP53 mutations in cancer using a novel conductometric biosensor. Biosensors and Bioelectronics, 276, 1-8.
DOI Scopus2
2025 Thangavelu, P. U., Lin, C. Y., Forouz, F., Tanaka, K., Dray, E., & Duijf, P. H. G. (2025). The RB protein: more than a sentry of cell cycle entry. Trends in Molecular Medicine, online(12), 1-16.
DOI
2025 Zare, E., Yaghoubi, S. M., Khoshnazar, M., Jafari Dargahlou, S., Machhar, J. S., Zheng, Z., . . . Mansoori, B. (2025). MicroRNAs in Cancer immunology: master regulators of the Tumor microenvironment and immune evasion, with therapeutic potential. Cancers, 17(13, article no. 2172), 1-38.
DOI
2025 Rose, M., Burgess, J. T., Cheong, C. M., Richard, I., Suraweera, A., Adams, M. N., . . . Bolderson, E. (2025). The inner nuclear membrane protein, Banf1, has an essential role in triple negative breast cancer cell proliferation and survival. Scientific Reports, 15(1), 25492.
DOI
2024 Huang, X., Leo, P., Jones, L., Duijf, P. H. G., Hartel, G., Kenny, L., . . . Punyadeera, C. (2024). A comparison between mutational profiles in tumour tissue DNA and circulating tumour DNA in head and neck squamous cell carcinoma - a systematic review. Mutation Research - Reviews in Mutation Research, 793(108477), 1-12.
DOI
2024 Avalos, B. D. L. P., Paquet, N., Tropée, R., Coulombe, Y., Palacios, H., Leung, J. W., . . . Dray, E. (2024). The protein phosphatase EYA4 promotes homologous recombination (HR) through dephosphorylation of tyrosine 315 on RAD51. Nucleic Acids Research, 52(3), 1173-1187.
DOI
2024 Joshi, V., Stacey, A., Feng, Y., Kalita de Croft, P., Duijf, P. H. G., Simpson, P. T., . . . McCart Reed, A. E. (2024). NDRG1 is a prognostic biomarker in breast cancer and breast cancer brain metastasis. Journal of Pathology: Clinical Research, 10(2, article no. e12364), 1-16.
DOI
2024 Balakittnen, J., Ekanayake Weeramange, C., Wallace, D. F., Duijf, P. H. G., Cristino, A. S., Hartel, G., . . . Punyadeera, C. (2024). A novel saliva-based miRNA profile to diagnose and predict oral cancer. International Journal of Oral Science, 16(14), 1-13.
DOI
2024 Bhatia, S., Khanna, K. K., & Duijf, P. H. G. (2024). Targeting chromosomal instability and aneuploidy in cancer. Trends in Pharmacological Sciences, 45(3), 210-224.
DOI
2024 Shahrouzi, P., Forouz, F., Mathelier, A., Kristensen, V. N., & Duijf, P. H. G. (2024). Copy number alterations: a catastrophic orchestration of the breast cancer genome. Trends in Molecular Medicine, 30(8), 750-764.
DOI
2024 Shahrouzi, P., Azimzade, Y., Brankiewicz Kopcinska, W., Bhatia, S., Kunke, D., Richard, D., . . . Duijf, P. H. G. (2024). Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug response. Breast Cancer Research, 26(1), 1-19.
DOI
2024 Joshi, V., Beecher, K., Lim, M., Stacey, A., Feng, Y., Jat, P. S., . . . McCart Reed, A. E. (2024). B7-H3 expression in breast cancer and brain metastasis. International Journal of Molecular Sciences, 25(7), 1-17.
DOI Scopus10 WoS11 Europe PMC10
2023 Rashidieh, B., Bain, A. L., Tria, S. M., Sharma, S., Stewart, C. A., Simmons, J. L., . . . Khanna, K. K. (2023). Alpha-B-Crystallin overexpression is sufficient to promote tumorigenesis and metastasis in mice. Experimental Hematology & Oncology, 12(1, article no. 4), 1-19.
DOI Scopus5 WoS5 Europe PMC3
2023 Adams, M. N., Croft, L. V., Urquhart, A., Saleem, M. A. M., Rockstroh, A., Duijf, P. H. G., . . . Richard, D. J. (2023). hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen-induced transcriptional response in prostate cancer. Prostate, 83(7), 628-640.
DOI
2023 Balakittnen, J., Weeramange, C. E., Wallace, D. F., Duijf, P. H. G., Cristino, A. S., Kenny, L., . . . Punyadeera, C. (2023). Noncoding RNAs in oral cancer. Wiley Interdisciplinary Reviews: RNA, 14(3, article no. e1754), 1-45.
DOI
2023 Bhatia, S., Gunter, J. H., Burgess, J. T., Adams, M. N., O'Byrne, K., Thompson, E. W., & Duijf, P. H. G. (2023). Stochastic epithelial-mesenchymal transitions diversify non-cancerous lung cell behaviours. Translational Oncology, 37(101760), 1-18.
DOI Scopus2
2023 Avalos, B. D. L. P., Tropee, R., Duijf, P. H. G., & Dray, E. (2023). EYA4 promotes breast cancer progression and metastasis through its role in replication stress avoidance. Molecular Cancer, 22(158), 1-18.
DOI
2022 Derakhshani, A., Javadrashid, D., Hemmat, N., Dufour, A., Solimando, A. G., Abdoli Shadbad, M., . . . Baradaran, B. (2022). Identification of common and distinct pathways in inflammatory bowel disease and colorectal cancer: a hypothesis based on weighted gene co-expression network analysis. Frontiers in Genetics, 13(848646), 1-12.
DOI
2021 Mansoori, B., Najafi, S., Mohammadi, A., AsadollahSeraj, H., Savadi, P., Mansoori, B., . . . Baradaran, B. (2021). The synergy between miR-486-5p and tamoxifen causes profound cell death of tamoxifen-resistant breast cancer cells. Biomedicine and Pharmacotherapy, 141(111925), 111925.
DOI
2021 Sahin, K. B., Shah, E. T., Ferguson, G. P., Molloy, C., Duijf, P. H. G., & Adams, M. N. (2021). Elevating CDCA3 levels enhances tyrosine kinase inhibitor sensitivity in TKI-resistant EGFR mutant non-small-cell lung cancer. Cancers, 13(18, article no. 4651), 4651.
DOI
2021 Kildey, K., Gandhi, N. S., Sahin, K. B., Shah, E. T., Boittier, E., Duijf, P. H. G., . . . Adams, M. N. (2021). Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy. Communications Biology, 4(1, article no. 638).
DOI
2021 Rashidieh, B., Molakarimi, M., Mohseni, A., Tria, S. M., Truong, H., Srihari, S., . . . Khanna, K. K. (2021). Targeting brf2 in cancer using repurposed drugs. Cancers, 13(15, article no. 3778), 3778.
DOI
2021 Mansoori, B., Silvestris, N., Mohammadi, A., Khaze, V., Baghbani, E., Mokhtarzadeh, A., . . . Baradaran, B. (2021). Mir‐34a and mir‐200c have an additive tumor‐suppressive effect on breast cancer cells and patient prognosis. Genes, 12(2, article no. 267), 1-17.
DOI
2021 Jakobsen, M. K., Traynor, S., Stæhr, M., Duijf, P. G., Nielsen, A. Y., Terp, M. G., . . . Gjerstorff, M. F. (2021). The cancer/testis antigen gene VCX2 is rarely expressed in malignancies but can be epigenetically activated using DNA methyltransferase and histone deacetylase inhibitors. Frontiers in Oncology, 10(584024), 1-12.
DOI
2021 Fernando, M., Duijf, P. H. G., Proctor, M., Stevenson, A. J., Ehmann, A., Vora, S., . . . Gabrielli, B. (2021). Dysregulated G2 phase checkpoint recovery pathway reduces DNA repair efficiency and increases chromosomal instability in a wide range of tumours. Oncogenesis, 10(5, article no. 41).
DOI
2021 Mansoori, B., Duijf, P. H. G., Mohammadi, A., Safarzadeh, E., Ditzel, H. J., Gjerstorff, M. F., . . . Baradaran, B. (2021). MiR-142-3p targets HMGA2 and suppresses breast cancer malignancy. Life Sciences, 276(119431), 119431.
DOI
2021 Wiegmans, A. P., Ward, A., Ivanova, E., Duijf, P. H. G., Adams, M. N., Najib, I. M., . . . Richard, D. J. (2021). Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancer. NAR Cancer, 3(2, article no. zcab022), 1-11.
DOI
2021 Safarzadeh, E., Mohammadi, A., Mansoori, B., Duijf, P. H. G., Hashemzadeh, S., Khaze, V., . . . Baradaran, B. (2021). STAT3 silencing and TLR7/8 pathway activation repolarize and suppress myeloid-derived suppressor cells from breast cancer patients. Frontiers in Immunology, 11(613215), 1-14.
DOI
2021 Mohammadi, A., Mansoori, B., Duijf, P. H. G., Safarzadeh, E., Tebbi, L., Najafi, S., . . . Baradaran, B. (2021). Restoration of miR-330 expression suppresses lung cancer cell viability, proliferation, and migration. Journal of Cellular Physiology, 236(1), 273-283.
DOI
2021 Tropée, R., de la Peña Avalos, B., Gough, M., Snell, C., Duijf, P. H. G., & Dray, E. (2021). The SWI/SNF subunit SMARCD3 regulates cell cycle progression and predicts survival outcome in ER+ breast cancer. Breast Cancer Research and Treatment, 185(3), 601-614.
DOI
2021 Suraweera, A., Duijf, P. H. G., Jekimovs, C., Schrobback, K., Liu, C., Adams, M. N., . . . Richard, D. J. (2021). Commd1, from the repair of dna double strand breaks, to a novel anti-cancer therapeutic target. Cancers, 13(4, article no. 830), 1-20.
DOI
2020 Shirjang, S., Mansoori, B., Mohammadi, A., Shajari, N., Duijf, P. H. G., Najafi, S., . . . Baradaran, B. (2020). Mir-330 regulates colorectal cancer oncogenesis by targeting BACH1. Advanced Pharmaceutical Bulletin, 10(3), 444-451.
DOI
2020 Shukla, A., Nguyen, T. H. M., Moka, S. B., Ellis, J. J., Grady, J. P., Oey, H., . . . Duijf, P. H. G. (2020). Chromosome arm aneuploidies shape tumour evolution and drug response. Nature Communications, 11(1, article no. 449), 1-14.
DOI
2020 Duijf, P. H. G. (2020). Low baseline pulmonary levels of cytotoxic lymphocytes as a predisposing risk factor for severe COVID-19. mSystems, 5(5, article no. e00741-20), 1-13.
DOI
2020 Fachal, L., Aschard, H., Beesley, J., Barnes, D. R., Duijf, P., & Dunning, A. M. (2020). Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 52(1), 56-73.
DOI Scopus123 WoS121 Europe PMC141
2020 Sinha, D., Nag, P., Nanayakkara, D., Duijf, P. H. G., Burgess, A., Raninga, P., . . . Khanna, K. K. (2020). Cep55 overexpression promotes genomic instability and tumorigenesis in mice.. Communications Biology, 3(1), 593.
DOI Scopus30 WoS27 Europe PMC29
2020 Mansoori, B., Mohammadi, A., Naghizadeh, S., Gjerstorff, M., Shanehbandi, D., Shirjang, S., . . . Baradaran, B. (2020). miR-330 suppresses EMT and induces apoptosis by downregulating HMGA2 in human colorectal cancer. Journal of Cellular Physiology, 235(2), 920-931.
DOI
2020 Mansoori, B., Duijf, P. H. G., Mohammadi, A., Najafi, S., Roshani, E., Shanehbandi, D., . . . Baradaran, B. (2020). Overexpression of HMGA2 in breast cancer promotes cell proliferation, migration, invasion and stemness. Expert Opinion on Therapeutic Targets, 24(3), 255-265.
DOI
2020 Abdel Fatah, T. M. A., Ball, G. R., Thangavelu, P. U., Reid, L. E., McCart Reed, A. E., Saunus, J. M., . . . Chan, S. Y. T. (2020). Association of sperm-associated antigen 5 and treatment response in patients with estrogen receptor-positive breast cancer. JAMA network open, 3(7, article no. e209486), 1-14.
DOI
2020 Suraweera, A., Duff, A., Adams, M. N., Jekimovs, C., Duijf, P. H. G., Liu, C., . . . Richard, D. J. (2020). Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer. British Journal of Cancer, 123(4), 591-603.
DOI
2020 Burgess, J. T., Bolderson, E., Adams, M. N., Duijf, P. H. G., Zhang, S. D., Gray, S. G., . . . O'Byrne, K. J. (2020). SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer. Scientific Reports, 10(1, article no. 18605), 1-10.
DOI
2020 Khanna, K. K., & Duijf, P. H. G. (2020). Complexities of pharmacogenomic interactions in cancer. Molecular & Cellular Oncology, 7(3, article no. e1735910), 1735910.
DOI
2019 Safarzadeh, E., Shahryar, H., Duijf, P. H. G., Mansoori, B., Khaze, V., Mohammadi, A., . . . Baradaran, B. (2019). Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer. Journal of Cellular Physiology, 234(4), 3515-3525.
DOI
2019 Brückmann, N. H., Bennedsen, S. N., Duijf, P. H. G., Terp, M. G., Thomassen, M., Larsen, M., . . . Gjerstorff, M. F. (2019). A functional genetic screen identifies the Mediator complex as essential for SSX2-induced senescence. Cell Death and Disease, 10(11, article no. 841), 1-12.
DOI
2019 Mansoori, B., Mohammadi, A., Ghasabi, M., Shirjang, S., Dehghan, R., Montazeri, V., . . . Baradaran, B. (2019). miR-142-3p as tumor suppressor miRNA in the regulation of tumorigenicity, invasion and migration of human breast cancer by targeting Bach-1 expression. Journal of Cellular Physiology, 234(6), 9816-9825.
DOI
2019 Li, A., Geyer, F. C., Blecua, P., Lee, J. Y., Selenica, P., Brown, D. N., . . . Stone, J. (2019). Homologous recombination DNA repair defects in PALB2-associated breast cancers. npj Breast Cancer, 5(1), 23-1-23-14.
DOI Scopus43 WoS45 Europe PMC42
2019 Brown, P., Tan, A. -C., El-Esawi, M. A., Liehr, T., Blanck, O., Gladue, D. P., . . . Zhou, Y. (2019). Large expert-curated database for benchmarking document similarity detection in biomedical literature search. Database: the journal of biological databases and curation, 2019(baz085), baz085-1-baz085-66.
DOI Scopus28 WoS36 Europe PMC13
2019 Li, A., Geyer, F., Blecua, P., Lee, J., Selenica, P., Brown, D., . . . Stone, J. (2019). Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers (npj Breast Cancer, (2019), 5, 1, (23), 10.1038/s41523-019-0115-9). npj Breast Cancer, 5(1).
DOI
2019 Al Emran, A., Marzese, D. M., Menon, D. R., Hammerlindl, H., Ahmed, F., Richtig, E., . . . Schaider, H. (2019). Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer. Epigenomics, 11(7), 723-737.
DOI
2019 Shomali, N., Shirafkan, N., Duijf, P. H. G., Ghasabi, M., Babaloo, Z., Yousefi, M., . . . Baradaran, B. (2019). Downregulation of miR-146a promotes cell migration in Helicobacter pylori-negative gastric cancer. Journal of Cellular Biochemistry, 120(6), 9495-9505.
DOI
2019 Mansoori, B., Mohammadi, A., Asadzadeh, Z., Shirjang, S., Minouei, M., Abedi Gaballu, F., . . . Baradaran, B. (2019). HMGA2 and Bach-1 cooperate to promote breast cancer cell malignancy. Journal of Cellular Physiology, 234(10), 17714-17726.
DOI
2019 Mansoori, B., Mohammadi, A., Gjerstorff, M. F., Shirjang, S., Asadzadeh, Z., Khaze, V., . . . Baradaran, B. (2019). miR-142-3p is a tumor suppressor that inhibits estrogen receptor expression in ER-positive breast cancer. Journal of Cellular Physiology, 234(9), 16043-16053.
DOI
2019 Bhatia, S., Monkman, J., Blick, T., Duijf, P. H. G., Nagaraj, S. H., & Thompson, E. W. (2019). Multi-omics characterization of the spontaneous mesenchymal-epithelial transition in the PMC42 breast cancer cell lines. Journal of Clinical Medicine, 8(8, article no. 1253), 1-31.
DOI
2018 Lin, C. Y., Shukla, A., Grady, J. P., Fink, J. L., Dray, E., & Duijf, P. H. G. (2018). Translocation breakpoints preferentially occur in euchromatin and acrocentric chromosomes. Cancers, 10(1), 1-19.
DOI
2018 Lin, C. Y., Beattie, A., Baradaran, B., Dray, E., & Duijf, P. H. G. (2018). Contradictory mRNA and protein misexpression of EEF1A1 in ductal breast carcinoma due to cell cycle regulation and cellular stress. Scientific Reports, 8(1, article no. 13904), 1-12.
DOI
2018 Joo, J. E., Dowty, J. G., Milne, R. L., Wong, E. M., Duijf, P., & Antill, Y. (2018). Heritable DNA methylation marks associated with susceptibility to breast cancer. Nature Communications, 9(1, article number 867), 1-12.
DOI Scopus83 Europe PMC78
2018 Shajari, N., Davudian, S., Kazemi, T., Mansoori, B., Salehi, S., Shahgoli, V. K., . . . Baradaran, B. (2018). Silencing of BACH1 inhibits invasion and migration of prostate cancer cells by altering metastasis-related gene expression. Artificial Cells, Nanomedicine and Biotechnology, 46(7), 1495-1504.
DOI
2018 Kalimutho, M., Sinha, D., Jeffery, J., Nones, K., Srihari, S., Fernando, W. C., . . . Khanna, K. K. (2018). CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer. EMBO Molecular Medicine, 10(9, article no. e8566), 1-22.
DOI
2017 Thangavelu, P. U., Lin, C. Y., Vaidyanathan, S., Nguyen, T. H. M., Dray, E., & Duijf, P. H. G. (2017). Overexpression of the E2F target gene CENPI promotes chromosome instability and predicts poor prognosis in estrogen receptor-positive breast cancer. OncoTarget, 8(37), 62167-62182.
DOI
2016 Vaidyanathan, S., Cato, K., Tang, L., Pavey, S., Haass, N. K., Gabrielli, B. G., & Duijf, P. H. G. (2016). In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis. Oncogene, 35(41), 5446-5455.
DOI
2016 Vaidyanathan, S., Thangavelu, P. U., & Duijf, P. H. G. (2016). Overexpression of Ran GTPase components regulating nuclear export, but not mitotic spindle assembly, marks chromosome instability and poor prognosis in breast cancer. Targeted Oncology, 11(5), 677-686.
DOI
2016 Thangavelu, P. U., Krenács, T., Dray, E., & Duijf, P. H. G. (2016). In epithelial cancers, aberrant COL17A1 promoter methylation predicts its misexpression and increased invasion. Clinical Epigenetics, 8(1, article no. 120), 1-13.
DOI
  • Targeting a common genetic alteration in glioblastoma, Neurosurgical Research Foundation, 16/09/2024 - 15/09/2026

  • Targeting genetic defects in glioblastoma, Neurosurgical Research Foundation, 15/09/2024 - 12/09/2025

Courses I teach

  • MEDI 3014 Current Topics in Medical Research (2024)

Date Role Research Topic Program Degree Type Student Load Student Name
2025 Principal Supervisor - Doctor of Philosophy Doctorate Full Time Mr Ming San Phong
2024 Co-Supervisor - Doctor of Philosophy Doctorate Full Time Miss Emma Luise Dorward
2024 Principal Supervisor - Doctor of Philosophy Doctorate Full Time Ms Shervindokht Farhangfar

Connect With Me

External Profiles

Other Links